A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC …
A Ichida, J Arita, E Hatano, S Eguchi, A Saiura… - Liver Cancer, 2023 - karger.com
Abstract Introduction: The phase III REFLECT trial demonstrated that lenvatinib was superior
to sorafenib in terms of progression-free survival (PFS), time to progression, and objective …
to sorafenib in terms of progression-free survival (PFS), time to progression, and objective …
A multidisciplinary treatment strategy with conversion surgery for hepatocellular carcinoma
H Shiozaki, K Furukawa, K Haruki… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Sorafenib was previously the only targeted therapy for hepatocellular
carcinoma (HCC). However, pharmaceutical therapy for HCC has undergone remarkable …
carcinoma (HCC). However, pharmaceutical therapy for HCC has undergone remarkable …
Surgical intervention after lenvatinib treatment in patients with advanced hepatocellular carcinoma
M Okuno, E Hatano, M Tada, T Nishimura… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: The survival and prognostic factors in patients with advanced
hepatocellular carcinoma (HCC) who underwent surgical intervention after lenvatinib …
hepatocellular carcinoma (HCC) who underwent surgical intervention after lenvatinib …
A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the …
Y Gyoda, H Ichida, F Kawano, Y Takeda… - Clinical Journal of …, 2024 - Springer
Conversion surgery for initially unresectable hepatocellular carcinoma appears to be
increasing in incidence since the advent of new molecular target drugs and immune …
increasing in incidence since the advent of new molecular target drugs and immune …
Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)
XLYLW Zhouc, TPJ Zhoue, HBFXX Cheng - 2024 - karger.com
Background: Immune checkpoint inhibitor (ICI)-based combination therapy modalities for
hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and …
hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and …
Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor (ICI)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)
X Liu, Y Lu, W Zhou, T Peng, J Zhou, H Bi, F Xia… - 2024 - karger.com
Background: Immune checkpoint inhibitor (ICI)-based combination therapy modalities for
hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and …
hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and …
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC …
AIJAE Hatanob, S Eguchid, ASHNJ Shindohg… - 2023 - karger.com
Abstract Introduction: The phase III REFLECT trial demonstrated that lenvatinib was superior
to sorafenib in terms of progressionfree survival (PFS), time to progression, and objective …
to sorafenib in terms of progressionfree survival (PFS), time to progression, and objective …
Lenvatinib 投与後に parenchymal sparing hepatectomy が可能となった巨大肝細胞癌の 1 例
田井優太， 森田剛文， 牧野光将， 井田進也… - 日本消化器外科学会 …, 2023 - jstage.jst.go.jp
切除困難な巨大肝細胞癌に対する術前治療として分子標的薬を用いた報告はいまだ少数である.
今回, 巨大肝細胞癌に対し術前に lenvatinib の投与により腫瘍が縮小し, 切除後の残肝容積を温存 …
今回, 巨大肝細胞癌に対し術前に lenvatinib の投与により腫瘍が縮小し, 切除後の残肝容積を温存 …